Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 8/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24815908 | 1.00 | KMT2A (0.39) | KMT2AMEN1MAPK1ITGB3ITGA2B | |
| SCHEMBL27218038 | 1.00 | KMT2A (0.39) | KMT2AMEN1MAPK1ITGB3ITGA2B | |
| SCHEMBL2549745 | 1.00 | KMT2A (0.39) | KMT2AMEN1MAPK1ITGB3ITGA2B | |
| SCHEMBL27218008 | 1.00 | KMT2A (0.39) | KMT2AMEN1MAPK1ITGB3ITGA2B | |
| SCHEMBL8271718 | 1.00 | KMT2A (0.39) | KMT2AMEN1MAPK1ITGB3ITGA2B | |
| SCHEMBL12852123 | 0.90 | DPP4 (0.40) | KMT2AMEN1MAPK1ITGB3ITGA2B | |
| SCHEMBL21157400 | 0.89 | ALDH1A1 (0.45) | KMT2AMEN1MAPK1ITGB3ITGA2B | |
| SCHEMBL8324848 | 0.88 | DPP4 (0.35) | KMT2AMEN1MAPK1ITGB3ITGA2B | |
| SCHEMBL12969913 | 0.86 | MEN1 (0.37) | KMT2AMEN1MAPK1ITGB3ITGA2B | |
| SCHEMBL8299304 | 0.86 | KMT2A (0.48) | KMT2AMEN1MAPK1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2505579-B1 | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof | ASTRAZENECA AB (SE) | 2014-11-05 | — | — | EP | claimed |
| EP-2517706-B1 | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof | ASTRAZENECA AB (SE) | 2014-06-25 | — | — | EP | claimed |
| US-20130012723-A1 | METHODS AND COMPOUNDS FOR PRODUCING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-10 | — | — | US | claimed |
| EP-2517706-A2 | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof | Bristol-Myers Squibb Company (US) | 2012-10-31 | — | — | EP | claimed |
| EP-2505579-A2 | Methods and compounds for producing dipeptidyl peptidase iv inhibitors and intermediates thereof | Bristol-Myers Squibb Company (US) | 2012-10-03 | — | — | EP | claimed |
| US-20100274025-A1 | METHODS AND COMPOUNDS FOR PRODUCING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-28 | — | — | US | claimed |
| US-20090018311-A1 | METHODS AND COMPOUNDS FOR PRODUCING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-15 | — | — | US | claimed |
| CN-115417794-B | Preparation method of saxagliptin intermediate | 扬州市三药制药有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| US-20230312571-A1 | RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF | FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| EP-4209494-A1 | RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF | Fujian Akeylink Biotechnology Co., Ltd. (CN) | 2023-07-12 | — | — | EP | disclosed |
| WO-2023093834-A1 | PYRROLIDINE ANTIVIRAL COMPOUND | 先声再明医药有限公司 | 2023-06-01 | — | — | WO | disclosed |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-02-21 | — | — | US | disclosed |
| WO-2006020664-A2 | AMMONOLYSIS PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR DPP IV INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2005115982-A1 | PROCESS FOR PRODUCING A DIPEPTIDYL PEPTIDASE IV INHIBITOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050260712-A1 | Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor | ASTRAZENECA AB (SE) | 2005-11-24 | — | — | US | disclosed |
| WO-2005106011-A2 | PROCESS FOR PREPARING DIPEPTIDYL IV INHIBITORS AND INTERMEDIATES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050090539-A1 | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof | ASTRAZENECA AB (SE) | 2005-04-28 | — | — | US | disclosed |
| WO-2005012249-A2 | ADAMANTYGLYCINE- BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2004052850-A2 | METHODS AND COMPOUNDS PRODUCING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100274025-A1 | METHODS AND COMPOUNDS FOR PRODUCING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREOF | DPP4, DPP3, DPP8 | KMT2A 4097/4885MEN1 3601/4885MAPK1 4078/4885 |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | PCNA, CD2BP2, CCNO | KMT2A 1719/4885MEN1 2512/4885MAPK1 1154/4885 |
| US-20050090539-A1 | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof | DPP4, DPP3, DPP8 | KMT2A 4097/4885MEN1 3601/4885MAPK1 4078/4885 |
| US-20090018311-A1 | METHODS AND COMPOUNDS FOR PRODUCING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREOF | DPP4, DPP3, DPP8 | KMT2A 4097/4885MEN1 3601/4885MAPK1 4078/4885 |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | KMT2A 3963/4885MEN1 3338/4885MAPK1 1034/4885 |
| US-20050260712-A1 | Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor | DNPEP, DPP4, PEPD | KMT2A 2694/4885MEN1 2318/4885MAPK1 2946/4885 |
| US-20230312571-A1 | RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOF | VIP, PREP, PRAP1 | KMT2A 3623/4885MEN1 1707/4885MAPK1 998/4885 |
| US-20130012723-A1 | METHODS AND COMPOUNDS FOR PRODUCING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREOF | DPP4, DPP3, DPP8 | KMT2A 4097/4885MEN1 3601/4885MAPK1 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.